Serving leading biopharmaceutical companies globally:

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Ranibizumab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Summary for ranibizumab

Tradenames:	1
Patents:	172
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ranibizumab

Recent Clinical Trials for ranibizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Wake Forest University Health Sciences	Phase 4
Sun Yat-sen University	Phase 4
Sudhalkar Eye Hospital	Phase 4

See all ranibizumab clinical trials

Pharmacology for ranibizumab

Mechanism of Action	Vascular Endothelial Growth Factor Receptor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions

Patent Text Search: US Patents for ranibizumab

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial		2039-03-29	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Innfocus, LLC (Miami, FL)	2024-12-03	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Genentech, Inc. (South San Francisco, CA)	2025-05-20	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Neurotech USA, Inc. (Lincoln, RI)	2025-12-30	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Innfocus, LLC (Miami, FL)	2024-12-03	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30	Start Trial	Bioresponse, L.L.C. (Boulder, CO)	2024-12-30	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for ranibizumab

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Spain	2709481	Start Trial
South Korea	20130141717	Start Trial
Japan	6552529	Start Trial
Japan	5937004	Start Trial
Israel	248632	Start Trial
Norway	20061139	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck

Johnson and Johnson

McKesson

Harvard Business School

Mallinckrodt

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.